2007
Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy
Daskivich T, Regan M, Oh W. Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy. Urology 2007, 70: 527-531. PMID: 17905110, DOI: 10.1016/j.urology.2007.04.035.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAndrogen AntagonistsAndrogensAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicDocetaxelDrug Resistance, NeoplasmHumansMaleMiddle AgedNeoplasms, Hormone-DependentPaclitaxelPrognosisProportional Hazards ModelsProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesSalvage TherapySurvival AnalysisTaxoidsTime FactorsConceptsProstate-specific antigen doubling timeAndrogen-independent prostate cancerEmergence of androgen-independent prostate cancerPatients treated with chemotherapyPSA nadirPSA valuesOverall survivalPrognostic informationShort prostate-specific antigen doubling timeEmergence of androgen independenceInstitutional prostate cancer databasePredictors of decreased OSAssociated with decreased OSAndrogen deprivation therapyCox proportional hazards regression modelsProstate cancer databaseType of chemotherapyProportional hazards regression modelsHazards regression modelsDoubling timeDeprivation therapyAndrogen independenceIntermediate prognosisProstate-specificPrognostic role
2006
Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy
Daskivich T, Regan M, Kantoff P, Oh W. Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. Journal Of Clinical Oncology 2006, 24: 4616-4616. DOI: 10.1200/jco.2006.24.18_suppl.4616.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerAndrogen deprivation therapyAssociated with decreased OSPSA-DTOverall survivalPSA nadirTaxane chemotherapyLow HbFailure of androgen deprivation therapyProstate specific antigen doubling timePredictors of decreased OSPSA nadir >Short PSA DTIndependent prostate cancerType of chemotherapyCox proportional hazards regressionHigh M stagePSA-VProportional hazards regressionLog-PSADeprivation therapyPSA valuesIntermediate prognosisPrognostic factorsPrognostic significance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply